Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kazuhiro Tabata"'
Autor:
Masahiro Nemoto, Yoshiaki Zaizen, Kensuke Kataoka, Kishio Kuroda, Kazuhiro Tabata, Andrey Bychkov, Hiromitsu Sumikawa, Takeshi Johkoh, Masahiro Aoshima, Yasuhiro Kondoh, Junya Fukuoka
Publikováno v:
PLoS ONE, Vol 16, Iss 1, p e0245147 (2021)
BackgroundHistopathologic factors predictive of nintedanib efficacy in idiopathic pulmonary fibrosis have not been studied. We aimed to describe the characteristics, focusing on histopathology, of idiopathic pulmonary fibrosis patients who did and di
Externí odkaz:
https://doaj.org/article/8ffabf6fcdb34eff889dca9e70b9b768
Autor:
Sayuri Nakamura, Kentaro Hayashi, Yuki Imaoka, Yuka Kitamura, Yuko Akazawa, Kazuhiro Tabata, Ruben Groen, Tomoshi Tsuchiya, Naoya Yamasaki, Takeshi Nagayasu, Junya Fukuoka
Publikováno v:
PLoS ONE, Vol 12, Iss 10, p e0186192 (2017)
Programmed cell death ligand-1 (PD-L1) expression may predict the response to both programmed cell death-1 and PD-L1 inhibitors in lung cancer. However, the extent of intratumoral heterogeneity of PD-L1 expression, which may cause false negative resu
Externí odkaz:
https://doaj.org/article/cf6d7115f7da423d9fae7687059c1452
Autor:
Yasuhiro Kondoh, Kishio Kuroda, Masahiro Aoshima, Kazuhiro Tabata, Junya Fukuoka, Masahiro Nemoto, Andrey Bychkov, Yoshiaki Zaizen, Kensuke Kataoka, Takeshi Johkoh, Hiromitsu Sumikawa
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 1, p e0245147 (2021)
PLoS ONE, Vol 16, Iss 1, p e0245147 (2021)
Background Histopathologic factors predictive of nintedanib efficacy in idiopathic pulmonary fibrosis have not been studied. We aimed to describe the characteristics, focusing on histopathology, of idiopathic pulmonary fibrosis patients who did and d
Autor:
Naoya Yamasaki, Takeshi Nagayasu, Ruben Groen, Junya Fukuoka, Sayuri Nakamura, Tomoshi Tsuchiya, Kentaro Hayashi, Kazuhiro Tabata, Yuka Kitamura, Yuko Akazawa, Yuki Imaoka
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 10, p e0186192 (2017)
PLoS ONE, Vol 12, Iss 10, p e0186192 (2017)
Programmed cell death ligand-1 (PD-L1) expression may predict the response to both programmed cell death-1 and PD-L1 inhibitors in lung cancer. However, the extent of intratumoral heterogeneity of PD-L1 expression, which may cause false negative resu